↑ Rising
Business
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Biotech stock Q32 surges 60% after promising alopecia trial results spark JAK inhibitor rivalry
Biotech Stocks
2 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✓
French biotech stock soars 34% after new data on experimental medicine
Shares of French biotech firm Abivax have surged following the release of new clinical safety data regarding its experimental ulcerative colitis medication.